摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-oxo-2H-chromene-6,7-diyl dibenzoate | 87997-42-0

中文名称
——
中文别名
——
英文名称
2-oxo-2H-chromene-6,7-diyl dibenzoate
英文别名
6,7-bis-benzoyloxy-coumarin;6,7-Bis-benzoyloxy-cumarin;esculetin 6,7-bis(benzoate);2-Oxo-2H-1-benzopyran-6,7-diyl dibenzoate;(7-benzoyloxy-2-oxochromen-6-yl) benzoate
2-oxo-2H-chromene-6,7-diyl dibenzoate化学式
CAS
87997-42-0
化学式
C23H14O6
mdl
——
分子量
386.361
InChiKey
QBDISGMDJVZAKB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    625.2±55.0 °C(Predicted)
  • 密度:
    1.360±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    29
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    78.9
  • 氢给体数:
    0
  • 氢受体数:
    6

SDS

SDS:63ac5ab4175c326db8ca9b0b4323dbba
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    一系列选择性针对人CA IX和CA XII碳酸酐酶的基于香豆素的新型化合物的抑制作用和结构见解
    摘要:
    香豆素衍生物是金属酶碳酸酐酶家族的一种特殊抑制剂(CA,EC 4.2.1.1)。几种香豆素对最相关且可药物处理的CA同工型显示出更高的亲和力和选择性。通过装饰天然化合物伞形酮(1),我们确定了一系列新的基于香豆素的化合物,它们对hCA IX和hCA XII亚型具有纳摩尔摩尔亲和力,显示出高的CA抑制作用,被认为是可开发抗肿瘤药物的靶标。经测试,活性最高的化合物是K i的有效抑制剂。其值等于众所周知的抑制剂乙酰唑胺(AAZ)的值,后者对普遍存在的hCA I和hCA II缺乏选择性。正如对接研究所建议的那样,缺少经典金属结合基团的香豆素在催化位点内不与锌离子相互作用,这是经典的磺酰胺类CAs所发现的。因此,所研究的抑制剂可能具有非经典的抑制作用方式,可阻止二氧化碳进入催化腔并阻止其转化为碳酸氢根离子。特别是,hCA XII化合物18i(K i值为5.5 nM)最具活性的抑制剂及其假定的水解产物可以在酶腔内建立H键相互作用网。
    DOI:
    10.1016/j.ejmech.2017.11.061
点击查看最新优质反应信息

文献信息

  • Esculetin derivatives and pharmaceutical composition
    申请人:Kureha Chemical Industry Co., Ltd.
    公开号:US05455268A1
    公开(公告)日:1995-10-03
    A pharmaceutical composition comprising a compound of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are, independently, a hydrogen atom, a saturated or unsaturated aliphatic acyl having 2 to 25 carbon atoms or benzoyl group and R.sup.3 is a hydrogen atom or alkyl group, and a pharmaceutically acceptable carrier is disclosed. Further, a novel compound of the general formula (I) wherein R.sup.1 and R.sup.2 are, independently, a hydrogen atom, pivaloyl, capryloyl, lauroyl, palmitoyl, stearoyl, linoleoyl, docosahexaenoyl, or benzoyl group, and R.sup.3 is a hydrogen atom or methyl group, is also disclosed.
    一种包含一般式(I)的化合物的药物组合物被揭示,其中R.sup.1和R.sup.2分别是氢原子、具有2至25个碳原子的饱和或不饱和脂肪族酰基或苯甲酰基,R.sup.3是氢原子或烷基,以及一种药学上可接受的载体。此外,还揭示了一种一般式(I)的新化合物,其中R.sup.1和R.sup.2分别是氢原子、偏戊酰基、辛酰基、月桂酰基、棕榈酰基、硬脂酰基、亚油酰基、二十二碳六烯酰基或苯甲酰基,R.sup.3是氢原子或甲基基团。
  • CONTROLLED RELEASE ORAL PREPARATIONS OF ESCULETIN AND ITS DERIVATIVES
    申请人:Kureha Chemical Industry Co., Ltd.
    公开号:EP1121931A1
    公开(公告)日:2001-08-08
    The present invention relates to an oral preparation of esculetin with controlled release. The oral preparation of esculetin with controlled release of the present invention comprises a gel-forming polymer base, preferably hydroxypropylmethylcellulose. The preparation may be coated with an enteric polymer base such as hydroxypropylmethylcellulose acetate succinate to thereby enhance solubility in the intestines. When orally administered, the preparation can continuously release esculetin. Thus, the administration frequency and dose can be reduced and a therapeutic effect on arthropathy can be established.
    本发明涉及一种控释埃斯库雷丁口服制剂。本发明的控释鱼藤素口服制剂包括凝胶形成聚合物基质,最好是羟丙基甲基纤维素。该制剂可涂覆羟丙基甲基纤维素醋酸琥珀酸酯等肠道聚合物基质,从而提高在肠道中的溶解度。 口服给药时,制剂可持续释放埃斯库莱汀。因此,可以减少给药次数和剂量,并对关节病产生治疗效果。
  • Semisynthesis, ex vivo evaluation, and SAR studies of coumarin derivatives as potential antiasthmatic drugs
    作者:Amanda Sánchez-Recillas、Gabriel Navarrete-Vázquez、Sergio Hidalgo-Figueroa、María Yolanda Rios、Maximiliano Ibarra-Barajas、Samuel Estrada-Soto
    DOI:10.1016/j.ejmech.2014.03.029
    日期:2014.4
    Asthma is a chronic inflammatory disorder that causes contraction in the smooth muscle of the airway and blocking of airflow. Reversal the contractile process is a strategy for the search of new drugs that could be used for the treatment of asthma. This work reports the semisynthesis, ex vivo relaxing evaluation and SAR studies of a series of 18 coumarins. The results pointed that the ether derivatives 1-3, 7-9 and 13-15 showed the best activity (E-max = 100%), where compound 2 (42 mu M) was the most potent, being 4-times more active than theophylline (positive control). The ether homologation (methyl, ethyl and propyl) in position 7 or positions 6 and 7 of coumarins lead to relaxing effect, meanwhile formation of esters generated less active compounds than ethers. The SAR analysis showed that it is necessary the presence of two small ether groups and the methyl group at position 4 (site 3) encourage biological activity through soft hydrophobic changes in the molecule, without drastically affecting the cLogP. (C) 2014 Elsevier Masson SAS. All rights reserved.
  • Über das Cichoriin und die Konstitution des Äskulins und des Skopolins
    作者:K. W. Merz
    DOI:10.1002/ardp.19322700806
    日期:——
  • US5455268A
    申请人:——
    公开号:US5455268A
    公开(公告)日:1995-10-03
查看更多